Meibomian Gland Dysfunction

4
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
Loteprednol/tobramycinPhase 41 trial
Active Trials
NCT01456780Completed60Est. Jun 2017
Azura Ophthalmics
Azura OphthalmicsIsrael - Tel Aviv
3 programs
2
1
AZR-MD-001 ointment/semi-solid drugPhase 2/31 trial
AZR-MD-001 ActivePhase 21 trial
AZR-MD-001 Low DosePhase 21 trial
Active Trials
NCT04391959CompletedEst. Jan 2021
NCT03652051CompletedEst. Oct 2022
NCT04314362CompletedEst. Jan 2021
Alcon
AlconFORT WORTH, TX
1 program
FID 114657N/A1 trial
Active Trials
NCT01079858Completed
Calico
CalicoLONG BEACH, CA
1 program
iLUX Treatment SystemN/A1 trial
Active Trials
NCT06278584CompletedEst. Feb 2022
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
senofilcon AN/A1 trial
Active Trials
NCT01819194Completed64Est. Aug 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch + LombLoteprednol/tobramycin
Azura OphthalmicsAZR-MD-001 ointment/semi-solid drug
Azura OphthalmicsAZR-MD-001 Active
Azura OphthalmicsAZR-MD-001 Low Dose
CalicoiLUX Treatment System
Johnson & Johnsonsenofilcon A
AlconFID 114657

Clinical Trials (7)

Total enrollment: 124 patients across 7 trials

NCT01456780Bausch + LombLoteprednol/tobramycin

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

Start: Aug 2011Est. completion: Jun 201760 patients
Phase 4Completed
NCT04314362Azura OphthalmicsAZR-MD-001 ointment/semi-solid drug

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Start: Jul 2020Est. completion: Jan 2021
Phase 2/3Completed
NCT04391959Azura OphthalmicsAZR-MD-001 Active

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Start: Jul 2020Est. completion: Jan 2021
Phase 2Completed
NCT03652051Azura OphthalmicsAZR-MD-001 Low Dose

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Start: Sep 2018Est. completion: Oct 2022
Phase 2Completed
NCT06278584CalicoiLUX Treatment System

iLux Treatment for Meibomian Gland Dysfunction

Start: Oct 2020Est. completion: Feb 2022
N/ACompleted
NCT01819194Johnson & Johnsonsenofilcon A

Contact Lens Comfort Relative to Meibomian Gland Status

Start: Mar 2013Est. completion: Aug 201364 patients
N/ACompleted
NCT01079858AlconFID 114657

Evaluation of FID 114657 in Dry Eye Subjects

Start: Feb 2010
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space